Core Insights - Rigel Pharmaceuticals announced the publication of final data from the Phase 1/2 ARROW study on pralsetinib for treating RET fusion-positive non-small cell lung cancer (NSCLC), highlighting its robust and durable responses with a manageable safety profile [1][2]. Study Results - The final data includes an additional 42 months of follow-up, reinforcing pralsetinib's role as a first-line treatment option for RET fusion-positive NSCLC patients [1][2]. - Among 259 patients with measurable disease, the overall response rate (ORR) was 70%, with 7% achieving complete responses and 63% partial responses [2]. - The ORR was higher at 78% for treatment-naïve patients compared to 63% for those who had prior platinum-based chemotherapy [2]. - Median overall survival (OS) was reported at 44.3 months for the overall measurable disease population, with treatment-naïve patients showing a median OS of 50.1 months [2]. - Median progression-free survival (PFS) was 13.1 months overall, with longer PFS in U.S. patients (25.9 months) compared to those in Asia (12.6 months) and Europe (12.8 months) [2]. Safety Profile - Pralsetinib was generally well tolerated, with a manageable toxicity profile; three treatment-related deaths were reported in treatment-naïve patients in Asia [2]. - No new safety signals were observed, and no hypersensitivity reactions were reported in patients who had received prior immunotherapies [2]. - Common adverse reactions included musculoskeletal pain, constipation, hypertension, diarrhea, fatigue, edema, pyrexia, and cough [9]. Clinical Implications - The study emphasizes the importance of early biomarker testing and suggests pralsetinib may be a valuable addition to treatment options for RET fusion-positive NSCLC [2]. - The intracranial response rate (CNS ORR) among patients with measurable CNS metastases at baseline was 53%, with a higher CNS ORR of 73% in evaluable patients [2]. Company Overview - Rigel Pharmaceuticals is focused on developing therapies for hematologic disorders and cancer, with pralsetinib being a key product in their portfolio [1][13].